We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Insulin-Like Growth Factor Binding Protein 5 (IGFBP5) Antibodies|
|Epitope||AA 76-114, N-Term Alternatives|
|Conjugate||This IGFBP5 antibody is un-conjugated Alternatives|
ELISA, Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-IGFBP5 AntibodyTarget Details IGFBP5 Application Details Handling Images
|Purpose||Rabbit IgG polyclonal antibody for Insulin-like growth factor-binding protein 5(IGFBP5) detection. Tested with WB, ELISA in Human.|
|Sequence||QGLRCLPRQD EEKPLHALLH GRGVCLNEKS YREQVKIER|
|Cross-Reactivity (Details)||No cross reactivity with other proteins.|
Rabbit IgG polyclonal antibody for Insulin-like growth factor-binding protein 5(IGFBP5) detection. Tested with WB, ELISA in Human.
Gene Name: insulin-like growth factor binding protein 5
Protein Name: Insulin-like growth factor-binding protein 5
|Purification||Immunogen affinity purified.|
|Immunogen||A synthetic peptide corresponding to a sequence at the N-terminus of human IGFBP5 (76-114aa QGLRCLPRQDEEKPLHALLHGRGVCLNEKSYREQVKIER), different from the related mouse and rat sequences by two amino acids.|
Target Details IGFBP5Product Details anti-IGFBP5 Antibody Application Details Handling Images back to top
|Alternative Name||IGFBP5 (IGFBP5 Antibody Abstract)|
Insulin-like growth factor-binding protein 5 is a protein that in humans is encoded by the IGFBP5 gene. The expression of IGFBP5 by stable transfection and adenovirus-mediated infection is inhibitory to growth in 2 human breast cancer cell lines. IGFBP5 expression leads to G2/M cell cycle arrest and apoptosis. Stable expression of IGFBP5 in the breast cancer cell lines also inhibits the formation and growth of tumors following injection in athymic mice. It is concluded that IGFBP5 is a growth inhibitor and proapoptotic agent in breast cancer cells. Additionally, IGFBP-5 is expressed by fibroblasts, myoblasts and osteoblasts, making it the predominant IGFBP found in bone extracts. It has a strong affinity for hydroxyapatite, allowing it to bind to bone cells. When bound to extracellular matrix, IGFBP-5 is protected from proteolysis and potentiates IGF activity, but when it is soluble, IGFBP-5 is cleaved to a biologically inactive 21 kDa fragment (1, 2).
Synonyms: IBP 5 antibody|IBP-5 antibody|IBP5 antibody|IBP5_HUMAN antibody|IGF binding protein 5 antibody|IGF BP5 antibody|IGF-binding protein 5 antibody|IGFBP 5 antibody|IGFBP-5 antibody|IGFBP5 antibody|Insulin like growth factor binding protein 5 antibody|Insulin-like growth factor-binding protein 5 antibody
|Research Area||Signaling, Diabetes, Metabolism, Growth Factors|
|Pathways||WNT Signaling, Carbohydrate Homeostasis, Myometrial Relaxation and Contraction, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Growth Factor Binding|
Application DetailsProduct Details anti-IGFBP5 Antibody Target Details IGFBP5 Handling Images back to top
WB: Concentration: 0.1-0.5 μg/mL, Tested Species: Human
ELISA: Concentration: 0.1-0.5 μg/mL, Tested Species: Human
Notes: Tested Species: Species with positive results.
Other applications have not been tested. Optimal dilutions should be determined by end users.
Antibody can be supported by chemiluminescence kit ABIN921124 in WB.
|Restrictions||For Research Use only|
HandlingProduct Details anti-IGFBP5 Antibody Target Details IGFBP5 Application Details Images back to top
|Reconstitution||Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.|
|Buffer||Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.
ImagesProduct Details anti-IGFBP5 Antibody Target Details IGFBP5 Application Details Handling back to top